Financials
Overview
MDxHealth operates on a calendar basis with its accounting year ending on Dec. 31. The company reports its consolidated financial statements under International Financial Reporting Standards (IFRS) and all amounts are in US Dollars. MDxHealth publishes a consolidated and audited Annual Report on an annual basis, a consolidated Interim Report for its June 30 half-year financial figures, and business/financial updates at the end of Q1 and Q3.
Furthermore, for the Annual General Shareholders’ Meeting, the company also publishes the non-consolidated Belgian-GAAP financial statements of the parent company. Prior to October 5, 2010, MDxHealth operated under the name OncoMethylome Sciences
2022 Reporting Calendar
- April 27, 2022: Q1-2022 business update
- May 25, 2022: Annual general shareholders’ meeting
- August 25, 2022: Publication of H1-2022 results
- October 27, 2022: Q3-2022 business update
3-year Snapshot
In “000” of USD
| Profit & Loss | 2021 | 2020 | 2019 |
|---|---|---|---|
| Revenues | 22,239 | 18,460 | 11,785 |
| Gross Profit | 10,564 | 8,044 | 30 |
| Research & Development Expenses | -6,673 | -4,543 | -8,897 |
| Selling & Marketing Expenses | -17,744 | -16,752 | -17,809 |
| General & Administrative Expenses | -14,149 | -13,990 | -15,196 | Other Operating Income (Expense), Net | 1,161 | 118 | -1,197 |
| Operating Loss | -26,841 | -27,123 | -43,169 |
| Financial Expense, Net | -2,162 | -1,539 | -506 |
| Loss Before Income Tax | -29,002 | -28,662 | -43,675 |
| Income Tax | 0 | 0 | 574 |
| Loss for the Year | -29,002 | -28,662 | -43,100 |
Assests
| 2021 | 2020 | 2019 | |
|---|---|---|---|
| Total Non-Current Assets | 8,466 | 8,765 | 9,721 |
| Total Current Assets | 66,606 | 23,091 | 30,907 |
| Of Which Cash & Cash Equivalents | 58,498 | 15,953 | 22,050 |
| Total Assets | 75,072 | 31,856 | 40,628 |
Liabilities and Shareholders’ Equity
| 2021 | 2020 | 2019 | |
|---|---|---|---|
| Total Equity | 46,899 | 5,849 | 19,724 |
| Non-Current Liabilities | 11,741 | 12,986 | 10,477 |
| Current Liabilities | 16,432 | 13,021 | 10,427 |
| Total Equity & Liabilities | 75,072 | 31,856 | 40,628 |
Cash Flows
| 2021 | 2020 | 2019 | |
|---|---|---|---|
| Operating Cash Flow | -22,548 | -20,244 | -22,289 |
| Investing Cash Flow | -885 | -537 | -73 |
| Financing Cash Flow | 66,498 | 14,290 | 17,965 |
| Cash & Cash Equivalents at End of Period | 58,498 | 15,953 | 22,050 |
Financial Reports
2021
2021 Interim Report: English I Français
2021 Consolidated Figures: English
2021 Board Report on Financial Statements: English I Français
2021 Full Non-consolidated Statutory Accounts: Français
2021 Annual Report (PDF): English I Français
2021 Annual Report (XBRL ZIP): English | Français
2020
2019
2018
2017
Full year 2017 Non Consolidated Statutory Account: français
Auditors Opinion: english | français
Board Report on 2017 Financial Statements “after correction to take into account a clerical drafting error”: english | français
2017 Consolidated figures: english
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
SEC Filings
Special Reports
The financial service for the shares of the company is provided in Belgium by KBS. Shareholders should inform themselves about the costs that other financial intermediaries may charge in connection with paying agency services.
Special Reports of the Board and Auditor
Board Report in relation to the capital increase of 8 November 2021 (ENG)
Board Report in relation to the capital increase of 8 November 2021 (FR)
Auditor Report in relation to the capital increase of 8 November 021 – contribution in kind (FR)
Auditor Report in relation to the capital increase of 8 November 2021 (FR)
Board Report in relation to the capital increase of 26 January 2021 (FR)
Board Report in relation to the capital increase of 26 January 2021 (EN)
Auditor Report in relation to the capital increase of 26 January 2021 (FR)
Report of the Statutory Auditor in relation to the equity investment by MVM, dated May 15, 2020 (EN)
Report of the Statutory Auditor in relation to the equity investment by MVM, dated May 15, 2020 (FR)
Board Report in relation to the equity investment by MVM, dated May 15, 2020 (EN)
Board Report in relation to the equity investment by MVM, dated May 15, 2020 (FR)
2019-09-Auditors Report art 596
2019-09-EN-Board Report art 596
2019-09-FR-Board Report art 596
2018-03-Auditors Report art 596
2018-03-EN-Board Report art 596
2018-03-FR-Board Report art 596
006 Board Report 596 (FR)[5].pdf
604 Board Report (FR) exec.pdf
583 596 598 Board Report and Plan (EN).pdf
583 596 598 Board Report and Plan (FR).pdf
R Mdx art 596-598 Plan d’options sur Action May 2017 – 2.500.000 SOP.pdf
Rapport special du conseil dadministration.article596.Nov_.2016.EN_.pdf
Rapport special du conseil dadministration.article596.Nov_.2016.EN_.pdf(FR).pdf
Rapport du commissaire, article 596, 31 octobre 2006 .pdf
Rapport du conseil d’administration. article 604 avril 2016.pdf
604 Board Report (FR) exec.pdf
Rapport du Commissaire, article 602, 18 septembre 2015.pdf
Rapport du Conseil d’Administration, article 602, 18 septembre 2015.pdf
Report of the Board, article 602, September 18, 2015.pdf
Rapport du commissaire – article 596, 23 juin 2015.pdf
Rapport du conseil d’administration, 23 juin 2015.pdf
Rapport du conseil d’administration, 4 novembre 2014.pdf
Rapport du conseil d’administration – articles 583-596-598 – 30 avril 2014.pdf
Rapport du commissaire – articles 596-598 – 30 avril 2014.pdf
Rapport du commissaire, articles 596 et 598, 24 juin 2013.pdf
Rapport du conseil d’administration, 24 juin 2013.pdf
Rapport du conseil d’administration, article 604, 30 avril 2013.pdf
Rapport du commissaire, articles 596 et 598, 28 juin 2012.pdf
Rapport du conseil d’administration, articles 603 juncto 596 et 598, 28 juin 2012.pdf
Rapport du conseil d’administration, articles 583:596:598, 18 avril 2012.pdf
Rapport du commissaire, articles 596:598, 19 avril 2012.pdf
Rapport du conseil d’administration, articles 583:596:598, 27 mai 2011.pdf
Rapport du commissaire, article 596, 27 mai 2011.pdf
Rapport du commissaire, article 596, 4 avril 2011.pdf
Rapport du conseil d’administration, article 603 juncto l’article 596, 4 avril 2011.pdf
Rapport du commissaire, Art. 582:596:598, 10 mai 2010.pdf
Rapport du conseil d’administration, articles 582:583:596:598, 21 juin 2010.pdf
Rapport du conseil d’administration, article 633, 10 mars 2010.pdf
Rapport du commissaire, article 596, 27 janvier 2009.pdf
Rapport du conseil d’administration, articles 583:596, 27 janvier 2009.pdf
Rapport du commissaire, article 596, 15 décembre 2008.pdf
Rapport du conseil d’administration, articles 603:596:589, 15 décembre 2008.pdf
Rapport du conseil d’administration, articles 583:596:589, 30 mai 2008 .pdf
Rapport du commissaire, article 596, 26 mai 2008.pdf
Rapport du conseil d’administration, articles 604, 27 mars 2008.pdf
Rapport du conseil d’administration, articles 603:596, 15 octobre 2007.pdf
Rapport du commissaire, article 596, 15 octobre 2007 .pdf
Rapport du conseil d’administration, articles 583:596:598, 25 mai 2007 .pdf
Rapport du commissaire, articles 596:598, 21 mai 2007 .pdf
Rapport du conseil d’administration, articles 583:596, 18 avril 2007.pdf
Rapport du commissaire, article 596, 16 avril 2007 .pdf
Rapport du conseil d’administration, articles 583:596, 8 november 2006.pdf
Listing prospectus - December 2021
2021 December Prospectus: English l Français
2021 Interim Report: English l Français
2020 Annual Report: English l Français
2021 November Board Report: English l Français
2021 November Auditor Report: Français
2021 November Auditor Report Contribution-in-Kind: Français
News: MDxHealth: English l Français
